China CanSinoBIO’s vaccine 57.5 per cent effective against COVID in phase-III trial: Study
The single-shot Ad5-nCoV vaccine, which CanSinoBIO co-developed with the Chinese military-backed Beijing Institute of…
Sign in
Sign in
Recover your password.
A password will be e-mailed to you.
Browsing Tag
Beijing Institute of Biotechnology
First COVID-19 vaccine human trial finds it is safe, induces immune response
According to the study of 108 adults, the vaccine produced neutralising antibodies, and a response mediated by the immune system's…